19th Vaccine Congress About

19th Vaccine Congress

7-10 September 2025 | Kyoto, Japan

Submit your abstracts by 23 May 2025!

Join us for the 19th Vaccine Congress

Join leading experts at the 19^th Vaccine Congress who will share their knowledge on the current developments and discoveries in the field.

#19vaccinecongress opens in new tab/window

Book your place at the Conference Dinner!

Organized by Vaccine opens in new tab/window, the premier journal for those interested in vaccine science, the congress will bring together leading experts from all over the world to share the latest cutting-edge discoveries in the field. Join us to present your own research, as well as form new relationships with potential collaborators!

The following quotes are from attendees that have visited previous Vaccine Congresses.

“A climate of collegiality and constructive feedback.”

“A good platform to meet the community, talk, discuss and share.”

“Really nice mix across spectrum of vaccine research from hesitancy and uptake to developing new vaccines - haven't come across that mix at other conferences.”

“This meeting was very well organized, professional, and timely. Relevant topics and state-of-the-art methods were presented by high caliber speakers. Multicultural attendance, panel and round table discussions, frequent breaks, provision of meals, and poster sessions allowed for considerable opportunity to network, deliberate, and make plans for moving science forward.”

“Great scientific content, easy to talk to people active in this field.”

“The Vaccine Congress brings together a wealth of global expertise, from basic science to service delivery, in one of the most important and powerful areas of contemporary international public health. It is instructive and inspirational in equal measure.”

Sebastian Taylor, Head of Global Operations, Royal College of Paediatrics and Child Health, London, UK

“The Vaccine Congress has an exciting agenda that will be of interest to all vaccinologists.”

Daniel Salmon, John Hopkins University, USA

JSV Session

We are excited to announce that a Joint Symposium with the Japanese Society of Vaccinology (JSV) and AMED-SCARDA will be held at the 19^th Vaccine Congress on Sunday, 7 September 2025.

Date: Sunday, 7 September 2025

Time: 13:30 – 17:30

Title: Vaccine science and design for the pandemic preparedness

Tentative program:

13:30 – 13:45	Opening Remarks: Takashi Nakano (President of JSV) Michinari Hamaguchi (SCARDA)
13:45 – 14:45	Session 1: Grand design platform and database for the development of innovative adjuvant and vaccine carrier
14:45 – 15:15	Coffee Break
15:15 – 16:15	Session 2: Innovative vaccine evaluation system for 100 days mission
16:15 – 17:15	Plenary talk: “Regulation of the germinal center B cell response to vaccination” Ali Ellebedy, Washington University in St. Louis, USA
17:15 – 17:30	Closing Remarks

The Joint JSV / AMED-SCARDA Symposium is free to attend for registered conference attendees and JSV members. Sign-up is required via the registration system opens in new tab/window (JSV members will be given the option to sign up to the Symposium without having to register to the Congress).

Abstracts are now invited on the following topics. They should be submitted using the online abstract submission system opens in new tab/window.

Abstract Submission Deadline: 23 May 2025

Conference topics

Systems Vaccinology
Vaccines Against STIs
Models for Vaccine Development and Evaluation
Pediatric Vaccines
Cancer Vaccines
Social and Political Impacts of Vaccination & Vaccine Policy
Vaccines Against Respiratory Viruses: Focus on Mucosal Immunity
One Health Vaccines
Vaccine Safety
Vaccines for older adults and strategies to tackle immunosenescence
Vaccine Technology
Hot Topics in Emerging Pathogens
Managing Vaccine Data
Veterinary Vaccines

Microphone in front of business people at conference

Keynote and plenary talks from renowned speakers

The program will include invited plenary lectures, contributed talks and poster sessions highlighting the latest research in vaccine science. The program will be curated by a committee of world class academic leaders in their respective fields.

View all Committee & Speakers

Side view of person typing on laptop keyboard

Discover and participate

Discover conference topics and learn about related events and how you can participate.

More information on how to participate

Sponsors & Exhibitors

Choose from a variety of sponsorship and commercial options to raise your profile and position your company as a thought leader in the community.

View all Sponsors & Exhibitors

Award winners

We are pleased to announce the following award winners:

Winner of the Host Country Early Career Researcher Award - Kaori Sano, National Institute of Infectious Diseases, Japan

Kaori Sano graduated from the Tokyo University of Agriculture and Technology in 2016, where she majored in veterinary medicine. She then pursued her PhD under the supervision of Dr. Hideki Hasegawa at the National Institute of Infectious Diseases (NIID) and received her PhD degree from the Tohoku University Graduate School of Medicine in 2020. In 2021, she joined Dr. Florian Krammer’s lab at the Icahn School of Medicine at Mount Sinai as a postdoctoral fellow and worked on research projects focusing on antibodies against influenza virus and SARS-CoV-2. She currently is a senior research scientist at the Influenza Research Center at NIID within the Japan Institute of Health Security (JIHS) and is involved in projects related to mucosal vaccine development and assessing antibody responses induced by viral infections and vaccinations.

Winner of the Early Career Scientist Award - Marios Koutsakos, The Peter Doherty Institute for Infection and Immunity, Australia

Dr Marios Koutsakos completed undergraduate and post-graduate studies at Imperial College in London. He subsequently undertook a PhD and post-doctoral training in the Department of Microbiology and Immunology, University of Melbourne, focusing on understanding protective immunity to influenza B viruses He is now a group leader at the Doherty Institute, working on dissecting the antigenic evolution of influenza viruses as well as the evolution of antibody-mediated immunity to influenza viruses in order to improve vaccine design.

Winner of the Schneerson Robbins Award - Mario Feldman, Washington University, St. Louis, USA

Prof. Mario Feldman earned his B.S. in Biotechnology from the National University of Rosario, Argentina, and pursued graduate studies at the Leloir Institute Foundation, affiliated with the University of Buenos Aires. He completed postdoctoral training in Belgium with Guy Cornelis, focusing on Type III Secretion Systems (T3SS), and in Switzerland with Markus Aebi, studying protein glycosylation in bacteria. He subsequently joined the Department of Biological Sciences at the University of Alberta in Edmonton, Canada. In 2015, he became a faculty member at Washington University School of Medicine in St. Louis, where he is now a full professor.

Dr. Feldman’s research encompasses various aspects of microbiology, with a primary focus on bacterial pathogenesis. Currently, his lab investigates the pathogenesis of Acinetobacter baumannii and the biogenesis of extracellular vesicles in human gut bacteria. He has authored more than 120 publications in leading scientific journals, and in recognition of his contributions to the field, he was elected a Fellow of the American Academy of Microbiology in 2021.

A pioneer in the field of bacterial glycoengineering, Dr. Feldman demonstrated the utility of bacterial glycosylation systems in the development of bioconjugate vaccines targeting bacterial pathogens. Bioconjugation relies on bacterial cells that simultaneously produce a polysaccharide antigen along with an engineered carrier protein and a conjugating enzyme to precisely link them together. This is a much simpler process than conventional chemical conjugation methods and has the potential to produce higher quality and more affordable vaccines. In 2016, he co-founded Omniose, a biotechnology company that now has approximately 20 employees and has secured ~$12 million in NIH funding. Omniose is currently collaborating with AstraZeneca to develop vaccines against bacterial infections.

Winner of the Jenner Award - Kanta Subbarao, Université Laval, Canada

On the individual page for the speaker Marios Koutsakos please can you add ‘Winner of the Early Career Scientist Award’ above his name if possible – if not can you add it in bold below his affiliation please.

On the individual page for the speaker Kaori Sano please can you add ‘Winner of the Host Country Early Career Researcher Award’

·On the individual page for the speaker Kanta Subbarao please can you add ‘Winner of the Jenner Award’

On the individual page for the speaker Mario Feldman please can you add ‘Winner of the Schneerson Robbins Award’

Conference deadlines

Abstract submission deadline for oral presentations – 23 May 2025

Submission for late posters and hot topics - 11 July 2024

Author notification deadline – 18 June 2025

Author registration deadline – 11 July 2025

Early bird deadline – 11 July 2025

Supporting publications

Vaccine

The official journal of The Japanese Society for Vaccinology opens in new tab/window.

Editor-in-Chief: Gregory A. Poland, MD

Vaccine opens in new tab/window is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas are welcomed. The submission categories opens in new tab/window as given in the Guide for Authors indicate where we receive the most papers. Papers outside these major areas are also welcome and authors are encouraged to contact us with specific questions. We also invite authors to submit relevant basic science and clinical reviews, methodological articles, opinion and commentary pieces, visual pieces, and letters. Authors are required to consult the Guide for Authors opens in new tab/window as the submission guidelines are dynamic and therefore subject to change.

Would you like to be a reviewer for Vaccine? If you think you would be a good referee for the Vaccine journal you can volunteer to review by visiting the Elsevier Reviewer Hub opens in new tab/window, where you can register your interest in volunteering for Vaccine. Further information can be found on our Reviewer page.

Vaccine opens in new tab/window Special Issue

Special Issue to summarize the latest developments presented at the 19^th Vaccine Conference held in Kyoto, Japan, 2025.

We are pleased to announce that selected papers presented at the 19^th Vaccine conference will be published in a Special Issue of Vaccine opens in new tab/window to summarize the latest progress in the field of Vaccinology. The special issue will be open for submissions from October 2025 onwards.

To discuss potential ideas, the suitability of your manuscript, or for further information please contact Dior Beerens: [email protected] opens in new tab/window(please do not email credit card information under any circumstances).

We look forward to receiving your contribution to the conference issue.

Vaccine: X

Vaccine: X opens in new tab/window is the open access companion journal of Vaccine and has the same aims and scope. The journal offers authors who want to publish in a gold open access journal the opportunity to make their work immediately and permanently accessible.